PL2379601T3 - Przeciwciało antyidiotypowe przeciw przeciwciału przeciw peptydowi amyloidu beta - Google Patents

Przeciwciało antyidiotypowe przeciw przeciwciału przeciw peptydowi amyloidu beta

Info

Publication number
PL2379601T3
PL2379601T3 PL09796629T PL09796629T PL2379601T3 PL 2379601 T3 PL2379601 T3 PL 2379601T3 PL 09796629 T PL09796629 T PL 09796629T PL 09796629 T PL09796629 T PL 09796629T PL 2379601 T3 PL2379601 T3 PL 2379601T3
Authority
PL
Poland
Prior art keywords
antibody against
amyloid beta
beta peptide
idiotype
idiotype antibody
Prior art date
Application number
PL09796629T
Other languages
English (en)
Inventor
Ulrich Essig
Wolfgang Hoesel
Kay-Gunnar Stubenrauch
Rudolf Vogel
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL2379601T3 publication Critical patent/PL2379601T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL09796629T 2008-12-22 2009-12-18 Przeciwciało antyidiotypowe przeciw przeciwciału przeciw peptydowi amyloidu beta PL2379601T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022235 2008-12-22

Publications (1)

Publication Number Publication Date
PL2379601T3 true PL2379601T3 (pl) 2017-02-28

Family

ID=40581970

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09796629T PL2379601T3 (pl) 2008-12-22 2009-12-18 Przeciwciało antyidiotypowe przeciw przeciwciału przeciw peptydowi amyloidu beta

Country Status (22)

Country Link
US (2) US8614297B2 (pl)
EP (1) EP2379601B1 (pl)
JP (1) JP5642702B2 (pl)
KR (2) KR20110086182A (pl)
CN (2) CN102257010A (pl)
AR (1) AR074816A1 (pl)
AU (1) AU2009331900A1 (pl)
BR (1) BRPI0923544B1 (pl)
CA (1) CA2746779C (pl)
CY (1) CY1118420T1 (pl)
DK (1) DK2379601T3 (pl)
ES (1) ES2595981T3 (pl)
HR (1) HRP20161398T1 (pl)
HU (1) HUE030478T2 (pl)
IL (1) IL213343A0 (pl)
LT (1) LT2379601T (pl)
MX (2) MX2011006641A (pl)
PL (1) PL2379601T3 (pl)
PT (1) PT2379601T (pl)
SI (1) SI2379601T1 (pl)
TW (1) TWI424162B (pl)
WO (1) WO2010072384A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
TW201348247A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3176580A1 (en) 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
EP3508849B1 (en) * 2016-08-31 2023-04-19 Eiken Kagaku Kabushiki Kaisha Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement
WO2020028266A1 (en) * 2018-08-03 2020-02-06 Cellular Research, Inc. Nuclei barcoding and capture in single cells
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
GB202410666D0 (en) * 2024-07-22 2024-09-04 Micromass Ltd Methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987002778A1 (en) 1985-10-22 1987-05-07 Cooper-Lipotech Solid-phase liposome immunoassay system
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
DE68928994T2 (de) 1988-11-03 1999-12-16 Igen International, Inc. Elektrochemilumineszente testverfahren
WO1990006515A1 (en) 1988-12-09 1990-06-14 Centocor, Inc. Anti-idiotopic immunometric assay
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005025516A2 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
WO2004092197A2 (en) 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
US20080127359A1 (en) * 2006-11-06 2008-05-29 Hermann Beck Method for producing anti-idiotypic antibodies
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途

Also Published As

Publication number Publication date
EP2379601A1 (en) 2011-10-26
JP2012513426A (ja) 2012-06-14
KR20110086182A (ko) 2011-07-27
AU2009331900A1 (en) 2010-07-01
PT2379601T (pt) 2016-10-04
CN102257010A (zh) 2011-11-23
CY1118420T1 (el) 2017-06-28
IL213343A0 (en) 2011-07-31
HUE030478T2 (en) 2017-05-29
SI2379601T1 (sl) 2016-11-30
BRPI0923544A2 (pt) 2016-01-26
WO2010072384A1 (en) 2010-07-01
KR20130088199A (ko) 2013-08-07
HRP20161398T1 (hr) 2016-12-16
US8614297B2 (en) 2013-12-24
KR101777899B1 (ko) 2017-09-13
DK2379601T3 (en) 2016-08-29
TW201030335A (en) 2010-08-16
EP2379601B1 (en) 2016-08-10
US9547010B2 (en) 2017-01-17
LT2379601T (lt) 2016-10-25
BRPI0923544B1 (pt) 2021-11-23
CA2746779C (en) 2017-01-24
JP5642702B2 (ja) 2014-12-17
ES2595981T3 (es) 2017-01-04
CN106990251A (zh) 2017-07-28
MX352117B (es) 2017-11-09
US20100167313A1 (en) 2010-07-01
AR074816A1 (es) 2011-02-16
TWI424162B (zh) 2014-01-21
CN106990251B (zh) 2019-12-27
CA2746779A1 (en) 2010-07-01
MX2011006641A (es) 2011-07-12
US20130323762A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
LT2379601T (lt) Antiidiotipiniai antikūnai, atpažįstantys antikūną prieš amiloido beta peptidą
HRP20180616T1 (hr) Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
ZA201000049B (en) Monoclonal antibeta amyloid antibody
IL196478A0 (en) Humanized antibody against amyloid beta
PL2074145T3 (pl) Humanizowane przeciwciało przeciw amyloidowi beta
PT2842967T (pt) Fab beta amilóide peguilado
ZA201002275B (en) Il-23 antibodies
GB0708002D0 (en) Antibodies
SI2146745T1 (sl) Penta-specifično protitelo
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en) Antibodies
IL236236A (en) Antibodies to the fam26f polypeptide
IL205073A0 (en) Anti-bst2 antibody
GB2450632B (en) Transport assembly
IL254065A0 (en) Human antibody against amyloid in the cell
EP2348042A4 (en) MODIFIED AMYLOID BETA PEPTIDE
IL206013A0 (en) Stat3 epitope peptides
GB0805921D0 (en) The radmoval valve V2
PL386231A1 (pl) Element mocujący
ZA200900313B (en) Humanized antibody against amyloid beta
GB0724185D0 (en) Antibodies